iPath Optimized Currency Carry ETN ICI
Set alert
36.05 USD 0.00 0.00%
At close · Jun 28
36.05 Day range 36.05
36.05 52-week range 37.90
- Open
- 36.05
- Prev close
- 36.05
- Mkt cap
- 0
- Vol
- 11
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 36.05
- High
- 36.05
News
- Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
- Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
- Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
- Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
- Tempus AI Taps Growing ICI Market With New xM Assay
- Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
- The growth rate of eight basic industries of the country was 3.6 percent in March.
Your note
Sign in to keep a note on ICI — it syncs with the Stock Master app.